A BILL 
To amend title XVIII of the Social Security Act to combat 
the opioid crisis by promoting access to non-opioid treat-
ments in the hospital outpatient setting. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Non-Opioids Prevent 
4
Addiction In the Nation Act’’ or the ‘‘NOPAIN Act’’. 
5
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
2 
•HR 3259 IH
SEC. 2. ACCESS TO NON-OPIOID TREATMENTS FOR PAIN. 
1
(a) IN GENERAL.—Section 1833(t) of the Social Se-
2
curity Act (42 U.S.C. 1395l(t)) is amended— 
3
(1) in paragraph (2)(E), by inserting ‘‘and sep-
4
arate payments for non-opioid treatments under 
5
paragraph (16)(G),’’ after ‘‘payments under para-
6
graph (6)’’; and 
7
(2) in paragraph (16), by adding at the end the 
8
following new subparagraph: 
9
‘‘(G) ACCESS TO NON-OPIOID TREATMENTS 
10
FOR PAIN.— 
11
‘‘(i) IN
GENERAL.—Notwithstanding 
12
any other provision of this subsection, with 
13
respect to a covered OPD service (or group 
14
of services) furnished on or after January 
15
1, 2022, and before January 1, 2027, the 
16
Secretary shall not package, and shall 
17
make a separate payment as specified in 
18
clause (ii) for, a non-opioid treatment (as 
19
defined in clause (iii)) furnished as part of 
20
such service (or group of services). 
21
‘‘(ii) AMOUNT
OF
PAYMENT.—The 
22
amount of the payment specified in this 
23
clause is, with respect to a non-opioid 
24
treatment that is— 
25
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
3 
•HR 3259 IH
‘‘(I) a drug or biological product, 
1
the amount of payment for such drug 
2
or biological determined under section 
3
1847A; or 
4
‘‘(II) 
a 
medical 
device, 
the 
5
amount of the hospital’s charges for 
6
the device, adjusted to cost. 
7
‘‘(iii) DEFINITION
OF
NON-OPIOID 
8
TREATMENT.—A 
‘non-opioid 
treatment’ 
9
means— 
10
‘‘(I) a drug or biological product 
11
that is indicated to produce analgesia 
12
without acting upon the body’s opioid 
13
receptors; or 
14
‘‘(II) an implantable, reusable, or 
15
disposable medical device cleared or 
16
approved by the Administrator for 
17
Food and Drugs for the intended use 
18
of managing or treating pain, 
19
that has demonstrated the ability to re-
20
place, reduce, or avoid opioid use or the 
21
quantity of opioids prescribed in a clinical 
22
trial or through data published in a peer- 
23
reviewed journal.’’. 
24
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
4 
•HR 3259 IH
(b) AMBULATORY SURGICAL CENTER PAYMENT SYS-
1
TEM.—Section 1833(i)(2)(D) of the Social Security Act 
2
(42 U.S.C. 1395l(i)(2)(D)) is amended— 
3
(1) by aligning the margins of clause (v) with 
4
the margins of clause (iv); 
5
(2) by redesignating clause (vi) as clause (vii); 
6
and 
7
(3) by inserting after clause (v) the following 
8
new clause: 
9
‘‘(vi) In the case of surgical services 
10
furnished on or after January 1, 2022, and 
11
before January 1, 2027, the payment sys-
12
tem described in clause (i) shall provide, in 
13
a budget-neutral manner, for a separate 
14
payment for a non-opioid treatment (as de-
15
fined 
in 
clause 
(iii) 
of 
subsection 
16
(t)(16)(G)) furnished as part of such serv-
17
ices in the amount specified in clause (ii) 
18
of such subsection.’’. 
19
(c) EVALUATION OF THERAPEUTIC SERVICES FOR 
20
PAIN MANAGEMENT.— 
21
(1) REPORT TO CONGRESS.—Not later than 1 
22
year after the date of the enactment of this Act, the 
23
Secretary of Health and Human Services (in this 
24
subsection referred to as the ‘‘Secretary’’), acting 
25
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
5 
•HR 3259 IH
through the Administrator of the Centers for Medi-
1
care & Medicaid Services, shall submit to Congress 
2
a report identifying— 
3
(A) limitations, gaps, barriers to access, or 
4
deficits in Medicare coverage or reimbursement 
5
for restorative therapies, behavioral approaches, 
6
and complementary and integrative health serv-
7
ices that are identified in the Pain Management 
8
Best Practices Inter-Agency Task Force Report 
9
and that have demonstrated the ability to re-
10
place or reduce opioid consumption; and 
11
(B) recommendations to address the limi-
12
tations, gaps, barriers to access, or deficits 
13
identified under subparagraph (A) to improve 
14
Medicare coverage and reimbursement for such 
15
therapies, approaches, and services. 
16
(2) PUBLIC CONSULTATION.—In developing the 
17
report described in paragraph (1), the Secretary 
18
shall consult with relevant stakeholders as deter-
19
mined appropriate by the Secretary. 
20
(3) EXCLUSIVE TREATMENT.—Any drug, bio-
21
logical product, or medical device that is a non- 
22
opioid 
treatment 
(as 
defined 
in 
section 
23
1833(t)(16)(G)(iii) of the Social Security Act, as 
24
added by subsection (a)) shall not be considered a 
25
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
6 
•HR 3259 IH
therapeutic service for the purpose of the report de-
1
scribed in paragraph (1). 
2
Æ 
21:46 Jun 24, 2021
H3259
tkelley on DSK125TN23PROD with BILLS
